PFS
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Guangwen Yuan, Ge Lou, Jundong Li, Mei Xu, Xiaowei Liu, Danbo Wang, Keqiang Zhang, Tao Zhu, Xiumin Li, Yi Huang, Wei Duan, Ke Wang, Qi Zhou, Guiling Li, Chen Yang, Jiajing Zhang, Haolin Sun, Renhong Tang, Qingshui Li, Lingying Wu
Nat Cancer 7(1) 182-193
In the SCORES study ( NCT04908787 ), women with ovarian cancer that progressed within 6 months after completing platinum-based therapy were randomized (2:1) to receive suvemcitug (1.5 mg kg-1), an antibody to vascular endothelial growth factor or placebo every 2 weeks, with chemotherapy (paclitaxel, topotecan or PEGylated liposomal doxorubicin). The primary endpoint was progression-free survival (PFS). The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, disease control rate, duration of response, quality of life, safety, pharmacokinetics and antidrug antibodies. Between June 5, 2021 and October 11, 2024, 421 participants were randomized (49.4% and 49.4% previously exposed to antiangiogenic agents and poly(ADP-ribose) polymerase inhibitors, respectively). Median PFS was 5.5 and 2.7 months in the suvemcitug and placebo arms, respectively (hazard ratio: 0.46, 95% confidence interval (CI): 0.35-0.60, P < 0.001), meeting the primary endpoint. Median OS was 15.3 versus 14.0 months, respectively (hazard ratio: 0.77, 95% CI: 0.60-0.99, P = 0.03). Decreased neutrophil count and decreased white blood cell count were the most common grade ≥3 treatment-emergent adverse events (TEAEs) in the suvemcitug arm. No suvemcitug-related grade 5 TEAE occurred. In conclusion, the addition of suvemcitug to chemotherapy significantly improved PFS and OS, with tolerable toxicities.
3 个 Figure · 5 个 KM 面板
Fig. 2. Survival outcomes. a , Kaplan–Meier curve of PFS at the first efficacy analysis in the full analysis set assessed by BIRC per RECIST (v.1.1). Number of participants: 281 and 140 in the suvemcitug and placebo arms, respectively. P < 0.0001. b , Kaplan–Meier curve of OS in the full analysis set at the final analysis. Number of participants: 281 and 140 in the suvemcitug and placebo arms, respectively. P = 0.03. PBO + CT, placebo plus chemotherapy; SV + CT, suvemcitug plus chemotherapy. Source data
Extended Data Fig. 1. Subgroup analyses of progression-free survival based on prior exposure to PARP inhibitors. a , patients who were PARP inhibitor naïve. Number of patients: 145 and 70 in the suvemcitug and placebo groups, respectively. P = 0.0004 . b , patients who had received prior PARP inhibitor therapy. Number of patients: 136 and 70 in the suvemcitug and placebo groups, respectively. P < 0.0001 . Source data
Extended Data Fig. 1 · Panel A
Panel A 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 1 · Panel B
Panel B 是同一 Extended Data Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 2. Supplementary and subgroup analyses of overall survival. a , Kaplan-Meier curve of overall survival of patients without subsequent antitumor therapy. Number of patients: 281 and 140 in the suvemcitug and placebo groups, respectively. P = 0.01 . Hypothetical estimands strategy was used for the supplemental analysis. 95% CI, 95% confidence interval; HR, hazard ratio; PBO + CT, placebo plus chemotherapy; SV + CT, suvemcitug plus chemotherapy. b , Forest plots for overall survival. Shown are the results of prespecified subgroup analyses of overall survival at the final analysis in the full analysis set. The hazard ratio (HR) for progression or death that is reported for all the randomized patients was based on a Cox proportional-hazards model. Source data
Extended Data Fig. 2 · Panel A
Panel A 是同一 Extended Data Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。